Get the Stockscreener App
83.46
6.95%
5.42
Bright Minds Biosciences Inc stock is traded at $83.46, with a volume of 311.24K.
It is up +6.95% in the last 24 hours and up +18.00% over the past month.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
See More
Previous Close:
$78.04
Open:
$79.51
24h Volume:
311.24K
Relative Volume:
1.90
Market Cap:
$649.92M
Revenue:
-
Net Income/Loss:
$-4.98M
P/E Ratio:
-63.34
EPS:
-1.3177
Net Cash Flow:
$-3.85M
1W Performance:
+1.63%
1M Performance:
+18.00%
6M Performance:
+197.97%
1Y Performance:
+103.02%
1-Day Range:
$76.00
$84.58
1-Week Range:
$75.11
$84.58
52-Week Range:
$23.18
$97.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Name
Bright Minds Biosciences Inc
Sector
Industry
Phone
-
Address
-
Compare DRUG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
83.46 | 607.71M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Initiated | BTIG Research | Buy |
| May-13-25 | Initiated | TD Cowen | Buy |
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-23-25 | Initiated | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-10-25 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | Robert W. Baird | Outperform |
View All
Bright Minds Biosciences Inc Stock (DRUG) Latest News
Bright Minds Biosciences’ (DRUG) Buy Rating Reaffirmed at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating for Bright Minds Biosciences (NASDAQ:DRUG) - MarketBeat
HC Wainwright Has Negative Outlook for DRUG Q1 Earnings - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Trading 4.2% HigherHere's Why - MarketBeat
H.C. Wainwright reiterates Buy rating on Bright Minds stock with $115 target - Investing.com Nigeria
Bright Minds Biosciences (NASDAQ:DRUG) Given “Buy” Rating at HC Wainwright - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Earns "Buy" Rating from HC Wainwright - MarketBeat
Bright Minds Biosciences (DRUG) Expected to Announce Quarterly Earnings on Monday - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Rating Increased to Hold at Wall Street Zen - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Sees Large Volume Increase – Time to Buy? - Defense World
How Bright Minds Biosciences Inc. stock performs in high volatility marketsDividend Stability Analysis & Superior Trading Ideas - bollywoodhelpline.com
Bright Minds Biosciences (DRUG) Projected to Post Earnings on Monday - MarketBeat
DRUG: R&D-driven net loss rose to $12.2M; $82.9M cash secures 12+ months' runway amid ongoing clinical trials - TradingView — Track All Markets
Will Bright Minds Biosciences Inc. stock reach Wall Street targetsLayoff News & Low Drawdown Trading Strategies - Улправда
How institutional buying supports Bright Minds Biosciences Inc. stock2025 Market Sentiment & Stock Market Timing Techniques - Улправда
Why Bright Minds Biosciences Inc. stock is popular among millennials2025 Market Overview & Weekly High Return Stock Forecasts - Улправда
TD Cowen analyst highlights 10+ potential biotech catalysts for 2026 By Investing.com - Investing.com Canada
Will Bright Minds Biosciences Inc. stock deliver shareholder valueMarket Performance Summary & Risk Controlled Stock Pick Alerts - Улправда
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 5.4%Here's What Happened - MarketBeat
Bullish Divergence Spotted in Tulsyan NEC Limited MomentumDividend Yield Trends & Fast Growing Investment Plans - earlytimes.in
Bright Minds Biosciences Inc Stock Analysis and ForecastCurrency Fluctuation Impact & Free Tools to Monitor Market Corrections - earlytimes.in
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 52-Week HighTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 7.3%Here's Why - MarketBeat
Bright Minds Biosciences has standout year with epilepsy drug in Phase II trials - Proactive financial news
Bright Minds Biosciences (NASDAQ:DRUG) Hits New 1-Year HighTime to Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Sets New 52-Week HighStill a Buy? - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 10.3%Time to Buy? - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Bright Minds Biosciences Inc. $DRUG - MarketBeat
What drives Bright Minds Biosciences Inc stock priceEnergy Sector Updates & High Yield Trading Signals - earlytimes.in
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 1-Year HighHere's Why - MarketBeat
Bright Minds Biosciences (NASDAQ:DRUG) Cut to Hold at Zacks Research - Defense World
Why Bright Minds Biosciences Inc. stock attracts high net worth investorsPortfolio Growth Summary & Fast Gaining Stock Strategy Reports - Newser
Cantor Fitzgerald Analysts Lower Earnings Estimates for DRUG - MarketBeat
An Intrinsic Calculation For Bright Minds Biosciences Inc. (CSE:DRUG) Suggests It's 44% Undervalued - simplywall.st
DRUG FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
(DRUG) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 7.2%Still a Buy? - MarketBeat
What technical signals suggest for Bright Minds Biosciences Inc. stockJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why - MSN
Cantor Fitzgerald reiterates Overweight rating on Bright Minds Biosciences stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on Bright Minds Biosciences stock - Investing.com Nigeria
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - MSN
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Target Price at $81.00 - Defense World
Bright Minds Biosciences Inc Stock (DRUG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):